LAB — STANDARD BIOTOOLS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1162194 ·
Last close
$0.67
Market Cap
$263.15M
52W High
$1.72
52W Low
$0.63
ADV30
1,357,470
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,104,000 | 10,535,000 | -7,829,000 | -26,758,000 | 627,218,000 | 270,026,000 | 87,247,000 |
| Mar 2026 | 21,146,000 | 11,308,000 | -9,416,000 | 127,068,000 | 639,114,000 | 265,772,000 | 77,991,000 |
| Dec 2025 | 23,795,000 | 11,382,000 | -21,924,000 | 19,283,000 | 567,754,000 | 120,863,000 | 143,463,000 |
| Sep 2025 | 19,552,000 | 9,484,000 | -23,467,000 | -34,687,000 | 539,636,000 | 129,418,000 | 139,977,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-80,300,000
Investing CF
$190,777,000
Financing CF
$330,000
CapEx
$-2,276,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,160,237,000
Inventory
$17,103,000
Receivables
$15,747,000
ST Investments
$206,693,000
EBIT TTM
$-72,161,000
Pretax Income TTM
$-90,981,000
Interest Exp TTM
$26,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$84,597,000
EBITDA
$-53,072,000
Free Cash Flow
$176,583,248
Enterprise Value
$-177,752,624
Total Cash
$476,719,008
Total Debt
$28,087,000
Shares Out
392,578,808
Trailing EPS
$-0.13
Book Value
$1.38
ROE
-11.2%
ROA
-6.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,331,000 | -93,305,000 | -74,896,000 | 567,754,000 | 143,463,000 | 424,291,000 | -74,343,000 |
| Dec 2024 | 91,008,000 | -87,006,000 | -138,885,000 | 612,345,000 | 140,623,000 | 471,722,000 | -143,454,000 |
| Dec 2023 | 106,340,000 | -63,039,000 | -74,656,000 | 323,067,000 | 471,118,000 | -148,051,000 | -43,287,000 |
| Dec 2022 | 97,948,000 | -102,616,000 | -190,098,000 | 390,310,000 | 471,777,000 | -81,467,000 | -89,370,000 |
TTM Snapshot
Revenues TTM
$65,682,000
NetIncome TTM
$78,205,000
OpCashFlow TTM
—
Assets (Latest)
$639,114,000
Forward EPS
$-0.01
Max Pain — expiry 2026-11-20
max pain strike: $1.00 · spot: $0.69 · call oi: 1,729 · put oi: 618
Expected Move to 2026-11-20:
±$0.22
(31.97%) —
implied range
$0.47 –
$0.91
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VOGX | Vogenx, Inc. | $259.82M | $17.49 | — |
| CYDY | CytoDyn Inc. | $272.66M | $0.20 | — |
| ACIU | AC Immune SA | $253.54M | $2.55 | — |
| AMRN | AMARIN CORP PLC\UK | $253.26M | $11.99 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $273.90M | $4.53 | — |
News headlines (Yahoo Finance, 1h cache)
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
2026-10-05 20:05 · Yahoo
Standard BioTools Provides Update on Sale of Mass Cytometry Business
2026-09-30 20:42 · Yahoo
Standard BioTools Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
2026-07-28 14:26 · Yahoo
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
2026-07-28 12:00 · Yahoo
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
2026-07-20 11:30 · Yahoo
Standard BioTools and Treeline Biosciences Announce Merger Agreement
2026-06-08 11:30 · Yahoo
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
2026-04-14 05:29 · Yahoo
Standard BioTools Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 00:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.